A C C Carvalho
Overview
Explore the profile of A C C Carvalho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreira A, Dalvi A, Bezerra A, Soares I, Goncalves L, Bhering M, et al.
Public Health Action
. 2025 Mar;
15(1):12-16.
PMID: 40028635
Setting: To appropriately triage and evaluate people with signs or symptoms of pulmonary TB, clinical, laboratory, and radiological variables, as well as biomarkers, have been prioritised to increase early detection....
2.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):506-519.
PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
3.
Carvalho A, Kritski A
Int J Tuberc Lung Dis
. 2022 Jun;
26(7):587-589.
PMID: 35768924
No abstract available.
4.
Akkerman O, Duarte R, Tiberi S, Schaaf H, Lange C, Alffenaar J, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(7):592-604.
PMID: 35768923
The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). A panel of 54 global experts in...
5.
Alffenaar J, Stocker S, Davies Forsman L, Garcia-Prats A, Heysell S, Aarnoutse R, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(6):483-499.
PMID: 35650702
Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance...
6.
Kritski A, Viveiros M, Carvalho A
Int J Tuberc Lung Dis
. 2022 May;
26(5):385-387.
PMID: 35505483
No abstract available.
7.
Migliori G, Marx F, Ambrosino N, Zampogna E, Schaaf H, van der Zalm M, et al.
Int J Tuberc Lung Dis
. 2021 Oct;
25(10):797-813.
PMID: 34615577
Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD...
8.
de Aguiar R, da Silva Vieira M, de Almeida I, de Paula Ramalho D, Ruffino-Netto A, Carvalho A, et al.
Pulmonology
. 2020 Jun;
28(5):350-357.
PMID: 32513638
Introduction: There are scarce data on the routine latent tuberculosis infection treatment (LTBIT) and factors associated with a non-completion in high tuberculosis burden countries. Therefore, in this study we aimed...
9.
Carneiro A, Costa G, Ferreira C, Ramos I, Sarandy M, Leite A, et al.
Int J Cardiol
. 2019 Jul;
299:243-248.
PMID: 31353153
Background: Chagas heart disease is the most important clinical manifestation of Trypanosoma cruzi infection. Pharmacological therapies have been proposed aiming to reduce inflammatory response and cardiac damage in infected hosts....
10.
Sulis G, Carvalho A, Capone S, Hamada Y, Giorgetti P, da Silva Martins P, et al.
Int J Tuberc Lung Dis
. 2018 Mar;
22(2):158-164.
PMID: 29506611
Background: Although the management of latent tuberculous infection (LTBI) is a core component of the End TB Strategy, there is limited information about the status of implementation of such interventions...